Treatment of respiratory diseases
AssigneeSosei R&D Ltd.
InventorsRobin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours. REFERENCE TO RELATED APPLICATION
Claims33
A dry powder composition for pulmonary delivery, comprising microparticles of glycopyrrolate.
A method for the treatment of a disease of the airways in a patient suffering from said disease, which comprises pulmonary delivery to said patient of a dry powder composition comprising microparticles of glycopyrrolate.
A dry powder inhaler comprising a dry powder composition for pulmonary delivery, said composition comprising microparticles of glycopyrrolate.
A process for the manufacture of an antimuscarinic agent in a controlled release formulation, comprising dissolving or suspending the agent in a hydrophobic material, and drying the material to form microparticles suitable for pulmonary delivery.
Dependencies are inferred from the claim text.